Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

		00540	
Vashington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cano Health, Inc.					2. Issuer Name and Ticker or Trading Symbol MSP Recovery, Inc. [LIFW]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last)	`	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 03/19/2024								Offic belo	cer (give tit w)	le	Othe belo	r (specify w)	
9725 NW 117TH AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) MIAMI	FL	, 3	33178											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Sta	ate) (Zip)		Rul	Rule 10b5-1(c) Transaction Indication						n							
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											ntended to							
		Table	1 - N	on-Deriva	tive S	Secui	rities	Ac	quirec	l, Dis	sposed of	, or B	enefici	ally Owi	ned				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Disposed Of 5)					Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following		nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Class A (Class A Common Stock 03			03/19/20	/2024				S		28,057	D	\$0.77	2,28	2,280,303		I	See Footnote ⁽²⁾	
Class A (Common Sto	ock		03/20/20)24				S		46,246	D	\$0.76	76 ⁽³⁾ 2,234,057 I			I	See Footnote ⁽²⁾	
Class A (Common Sto	ock		03/21/20	024				S		43,711	D	\$0.75	75(4) 2 100 246			See Footnote ⁽²⁾		
		Та	ble II								oosed of, convertib				ed				
1. Title of Derivative Security (Instr. 3)	rative Conversion Date Execution Date, if any				Transaction of Code (Instr. 8) Si Ai (A		osed) : 3, 4	6. Date Expira (Mont	ation D		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.76 to \$0.795. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 2. Reflects securities held directly by Cano Health, LLC, an indirect subsidiary of the Issuer.
- 3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.75 to \$0.775. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.75 to \$0.771. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Cano Health, Inc., By: /s/ David J. Armstrong, Name: David J. Armstrong, Title:

03/21/2024

General Counsel

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.